MedPath

Phase II study of combination chemotherapy with S-1 plus Avastin in unresectable or recurrent colorectal cancer after failure of prior chemotherapy, including irinotecan and oxaliplatin regimens.

Phase 2
Recruiting
Conditions
colorectal cancer
Registration Number
JPRN-UMIN000002308
Lead Sponsor
Translational Research Informatics Center(TRI)
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

Active infections (e.g., patients with pyrexia of 38'C or higher) Continuous treatment with steroids Serious complications (e.g., pulmonary fibrosis, interstitial pneumonitis, heart failure, renal failure, hepatic failure, or poorly controlled diabetes and hypertension) Patients with electrocardiographic abnormalities, with cardiac disorder that would clinically preclude the execution of the study judged by the investigator. Moderate or severe ascites or pleural effusion requiring treatment Active double cancer prior therapy radiotherapy prior therapy S-1 Pregnant women, possibly pregnant women, women wishing to become pregnant, and nursing mothers. Men who are currently attempting to conceive children. Serious drug hypersensitivity or a history of drug allergy Treatment with flucytosine Metastasis to the CNS Thrombosis, cerebral infarction, myocardial infarction, or pulmonary embolism History or evidence of inherited bleeding diathesis or coagulopathy with the risk of bleeding (Patients who treated low aspirin therapy(<325 mg/day) can be enrolled.) Major surgical procedure, open biopsy, or clinically significant traumatic injury within 4 weeks Severe mental disorder Judged ineligible for participation in the study by the investigator for safety reasons.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Disease control rate
Secondary Outcome Measures
NameTimeMethod
Response rate, Progression free survival, Overall survival, frequency of adverese event
© Copyright 2025. All Rights Reserved by MedPath